Why the study?
The study was conducted to assess the prevalence, structure, and features of aspirin-induced gastroduodenal lesions in patients with chronic CAD and to outline therapeutic options.
Does the addition of rebamipide to pantoprazole improve mucosal reconstruction and reduce pro-inflammatory cytokines compared to pantoprazole alone in patients with chronic CAD and aspirin-induced gastroduodenal lesions?
Observational (n=340)
Does the addition of rebamipide to pantoprazole improve mucosal reconstruction and reduce pro-inflammatory cytokines compared to pantoprazole alone in patients with chronic CAD and aspirin-induced gastroduodenal lesions?
Answers are grounded in this paper and cite their sources.
In patients with chronic CAD and aspirin-induced gastroduodenal lesions, adding rebamipide to pantoprazole improves mucosal healing and reduces systemic inflammation compared to pantoprazole alone.
Aim. To assess the prevalence, structure, and features of aspirin-induced gastroduodenal lesions in patients with chronic coronary artery disease (CAD) and outline therapeutic options. Material and methods . The study included 340 patients with chronic CAD who received long-term low-dose acetylsalicylic acid (ASA) therapy. The diagnosis of chronic CAD was verified using a complex examination with selective coronary angiography (SCA). Further, esophagogastroduodenoscopy was performed in patients with chronic CAD to diagnose aspirin-induced gastroduodenal lesions. We also assessed their prevalence and structure. An endogenous prostaglandin-inducer rebamipide (300 mg daily) in combination with a proton pump inhibitor (PPI) pantoprazole were used to treat aspirin-induced gastroduodenal lesions. The comparison group consisted of patients with chronic CAD who received only pantoprazole. To clarify the pathogenesis of aspirin-induced gastroduodenal lesions before and after treatment, the levels of following serum pro-inflammatory cytokines were determined: interleukin-6 (IL-6), interleukin-1-beta (IL-1β), tumor necrosis factor alpha (TNF-α). The control group consisted of patients with chronic CAD and without signs of gastrointestinal lesions. Statistical processing was carried out using Statistica 10.0 software package. Results . Aspirin-induced gastroduodenal lesions were recorded in 15% of patients. Results of esophagogastroduodenoscopy revealed that gastric erosions of body and antrum prevailed among aspirin-induced lesions. The level of pro-inflammatory cytokines in these patients was significantly higher than in patients of control group. Therapy with PPI resulted in a positive endoscopic response in 19 of 25 patients and a slight decrease in cytokines. Combination of PPI with rebamipide led to mucosal reconstruction in all subjects and a statistically significant decrease in levels of serum pro-inflammatory cytokines. Conclusion. The current study showed aspects of development and possible therapeutic options in aspirin-induced gastrointestinal lesions in patients with chronic CAD.
No takes yet. Share an insight, caveat, or question.
Borovkova et al. (2020) conducted an observational in Chronic coronary artery disease with aspirin-induced gastroduodenal lesions (n=340). Rebamipide in combination with pantoprazole vs. Pantoprazole alone was evaluated on Mucosal reconstruction / positive endoscopic response.
Synapse has enriched 10 related papers. Consider them for comparative context: